According to Foster City, Calif.-based Gilead, Vemlidy is the first drug approved to treat this disease in almost a decade.
Vemlidy demonstrates similar antiviral efficacy at a dose one-tenth the size of Gilead’s other hepatitis B drug Viread, which gained FDA approval in 2001.
More articles on supply chain:
Trucking industry hopeful Trump will loosen regulations, increase road spending
Leverage data analytics to control cath lab costs
FDA updates citizen petition regulations to prevent delays in drug approvals
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
